Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The mysterious dilution....
It's pathetic how they can't get it to close below .32.
You stated the market cap will be 400 million upon approval but then said approval is priced in. Which premise should we assume to be your position going forward?
Am I the only one here who doesn't understand how approval can be priced in if you believe the market cap will be 400 million on approval? Not being critical, just want clarity on the discrepancies posted.
So which is it, approval priced in or not? Logic says that if it's priced in the market cap on 7/14 would be the same as it is today. Let me know where my math is wrong...
"Said another way, I anticipate ELTP's market cap to increase to somewhere between $300MM and $400MM upon the announcement of ELI200 approval."
Like the logic that'll produce an overnight market cap increase of 76 million after the 10k is issued?
Where are you guys getting this 800 million shares outstanding???
It's because the market cap is increasing 76 million once the 10k drops. He said it himself.
He's waiting for the 10k to drop when the market cap is going to increase 76 million overnight with no impact of the 214 million shares of dilution.
Not as funny as your claim of a 300 million market cap supported by dilution. Somehow 214 million shares are going to be reflected on the 10k without dilution to support a 300 million market cap?
Hey, let's add 214 million shares and expect to increase our market cap 76 million dollars.
Check back with me after the 10k is released, this will be funny.
Yup, 214 million shares issued at today's price to get to your 300 million market cap. Volume supports your claim....
And when non-ADF products are removed so will follow the generic pricing. Thus, market potential will be much higher than it is today.
I doubt it since insiders hold over 17% of the shares. I know I don't check the PPS of my portfolio unless it's over 50% of my holdings. What percentage of your portfolio is Elite?
They can't even get it below .32, pathetic if you ask me.
Correction, 86 days for KMPH.
The response from IR, last week Thursday, was that most abuse deterrent formulation NDA's are referred to an advisory committee. The FDA needs to inform the applicant 15 days in advance. As of this point the FDA hasn't notified Elite.
I tried to benchmark the dates with other NDA submissions but couldn't draw a parallel between PDUFA date and advisory date notification. KMPH was notified 68 days prior to PDUFA and Collegium was around 65 days. That's quite a variance. If we haven't heard anything by June 29th we haven't been referred to the advisory committee. I suspect that's a great sign but I'm expecting an advisory committee.
Next week KMPH has theirs and it's public record. Should get a good feel for the process really quick.
Hope this helps.
Does anyone know whether the ADF NDA's being reviewed by the FDA 6/7 & 6/8 were designated priority review and their PFUFA dates?
Teva & Pfizer
So enlighten us on the number of outstanding shares. Please use data.
Thought I'd check in since the market is closed. Curious to see how it did.
They can't even calculate the market cap properly. Sheesh, I knew that without even looking.
He's not even in the right zip code. It shows, post was deleted. Need to update your script. Who running the show over there??? Lol
What have I been wrong about?
Might wanna check the market cap #
Very insightful, can I get a PPS update every 5 minutes or should I just wait until the closing bell?
Burn shorty burn!
There will be another PR but timing isn't dictated by ELTP, just wait, my popcorn is ready.
Shorts will get burned well before 7/14. We've got 2-3 more catalysts before then. I'm waiting for the first shoe to drop any day now. I'm not going to do the shorts any favors and let them know what these catalysts are.
That's why the volume is so low.
That is correct, between $1.50 & $1.60, good info can be found here: http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:fibonacci_retracemen
That is correct, between $1.50 & $1.60, good info can be found here: http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:fibonacci_retracemen
I bought in at .115 years ago, sold my trading shares on the run up and performed a Fibonacci analysis and bought in early Fall 2015 when the 66% retracement hit. That was .19.
Everything is a matter of perspective and I'm sorry you'll incur a nice tax write off when you sell before 7/14.
When news drives your investment thesis you gravitate towards the National Inquirer.
Why would we need to work with Purdue?
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079298.pdf
IV. TYPES OF WAIVERS AND REDUCTIONS
According to section 736(d) of the Act, FDA will grant a waiver of or reduction in one or more user fees assessed under section 736(a) of the Act where it finds that an applicant meets the eligibility criteria under one of the following provisions:
• A waiver or reduction is necessary to protect the public health.
• The assessment of the fee would present a significant barrier to innovation because of
limited resources available to the person or other circumstances.12
• The applicant is a small business submitting its first human drug application to the Secretary for review.
Can Purdue somehow magically convince the FDA that it's next submission would be the first application? We've already received the waiver without Purdue.
You are a long ways from breaking into the starting lineup:
https://en.wikipedia.org/wiki/Sixth_man
Here's one, Embeda is extended release, not immediate release. Another one, ELI-200 is Oxycodone Hydrochloride and EMBEDA is morphine sulphate.
"SequestOxTM is an immediate-release Oxycodone Hydrochloride containing sequestered Naltrexone which incorporates 5 mg, 10 mg, 15 mg, 20 mg and 30 mg doses of oxycodone into capsules. "
"EMBEDA capsules consist of extended-release morphine sulfate and sequestered naltrexone hydrochloride, an opioid antagonist. Naltrexone is intended to remain sequestered when the product is taken as directed. "
More differences can be found here:
http://www.pharmacychoice.com/news/article.cfm?Article_ID=1164141
As they are traded on the OTCBB they are not subject to SEC registration requirements. Absent this requirement one might ask why a company would voluntarily subject itself to SEC registration requirements when:
1. They are not required to be registered with the SEC to be listed on the OTCBB.
2. The costs to implement such requirements .
Quote:
"ELTP is not making these filings out of the goodness of their hearts or to provide transparency above and beyond what they are required to."
By being SEC registered ELTP is providing transparency above and beyond the requirements of the exchange they are listed on. This is important to understand especially when investing in OTC stocks.
One might infer that subjecting to SEC reporting requirements, when not required, demonstrates one of many steps to uplist to an exchange that requires it's registrants to be meet SEC registration requirements. But I don't have to point that out since it's been freely discussed on CC's and is even outlined in the investors presentation.
A Company's Obligations on the OTCQX, OTCQB and OTC Pink Marketplaces
Financial Reporting - Many companies are not subject to SEC registration requirements, and therefore, do not make regular filings of financial information and other corporate events with the SEC. Companies are not required to provide financial information to OTC Markets Group; however in order for investors to make informed trading decisions, many companies elect to provide disclosure. For a detailed explanation of SEC registration and reporting requirements and the exemptions available from those requirements, please see the SEC's Small Business Question and Answer Page
http://www.otcmarkets.com/learn/otc-company-reporting
Might want to check your facts. The above statement is not opinion....
10-20% is the typical threshold for modern day shareholders rights plan.
You might also want to read this article:
http://www.valuewalk.com/2015/01/u-s-firms-rushing-adopt-protective-poison-pills-factset/
You'll notice that poison pills exist for reasons other than hostile takeover defense.
#2 You're assuming the acquirer of over 15% of the shares wants to raise their cost basis to get to that 15%? Don't you know that the transactions would be broken up and spread out to prevent such a spike in volume and price appreciation?
"One 2005 study by FactSet found that companies using poison pills were able to raise their price tag 24% higher than companies without such plans."
#3 Is complete BS, name one company that wants to give away 15% meaningful ownership rights.
What's makes the risk of hostile takeover nonexistent compared to when it was enacted?
You seriously think the poison pill is useless? You do know that hostile takeovers aren't a once and a lifetime event right?
I can attest that it's not gagged too. The info I received would not have been issued under a gag.